Vol 24, No 5 (2017)
Original articles — Clinical cardiology
Published online: 2017-02-15

open access

Page views 2023
Article views/downloads 1278
Get Citation

Connect on Social Media

Connect on Social Media

Prognostic importance of central thrombus in hemodynamically stable patients with pulmonary embolism

Aysegul Senturk1, Savas Ozsu, Serap Duru, Ebru Cakır, Sevinc Sarinc Ulaslı, Ezgi Demirdogen, Servet Kayhan, Aygul Guzel, Fatih Yakar, Serdar Berk
Pubmed: 28248408
Cardiol J 2017;24(5):508-514.


Background: The association between mortality and localization of central thrombus in hemodynamically stable patients with pulmonary embolism (PE) is unclear. Sufficient data are not available to help clinicians to select between low molecular weight heparin (LMWH), unfractionated heparin (UFH) and thrombolytics for the management of central thrombus. The present study aims to investigate whether central thrombus in the pulmonary artery affects 30-day mortality rate, and to compare the outcomes of different treatment approaches in patients with central thrombus.

Methods: This multi-central, prospective, observational study included 874 hemodynamically stable patients with PE confirmed by multidetector computed tomography scan. The localization of the emboli was evaluated and categorized as central (saddle or at least one main pulmonary artery), lobar or distal. The primary study outcome was 30-day all-cause mortality.

Results: Localization of the emboli was central in 319 (36.5%) patients, lobar in 264 (30.2%) and distal in 291 (33.2%) patients. Seventy-four (8.5%) patients died during the 30-day follow-up period. All-cause mortality rate was 11.9%, 6.8% and 6.2% in patients with central, lobar, and distal emboli, respectively (p < 0.001). Multivariate analysis did not show that hemodynamically stable central thrombus was an independent predictor of mortality. Additionally, mortality rate was not significantly different between UFH, LMWH and thrombolytic therapy groups.

Conclusions: The present study showed that central thrombus was not an independent predictor of mortality in hemodynamically stable PE patients. LMWH and UFH were similarly effective in the treatment of this patient group.  

Article available in PDF format

View PDF Download PDF file


  1. Giancarlo A, Becattini C. Acute pulmonary embolism. N Engl J Med. 2010; 363(19): 266–274.
  2. Paiva L, Barra S, Providência R. Pulmonary embolism risk stratification: where are we heading? Eur Respir J. 2014; 43(1): 298–300.
  3. Fei J, Tang Y, Wu J, et al. Thrombolytic and anticoagulant therapy for acute submassive pulmonary embolism. Exp Ther Med. 2014; 7(1): 103–108.
  4. Ozsu S, Ozlu T, Sentürk A, et al. TUPEG Study Investigators. Combination and comparison of two models in prognosis of pulmonary embolism: results from TUrkey Pulmonary Embolism Group (TUPEG) study. Thromb Res. 2014; 133(6): 1006–1010.
  5. Torbicki A, Perrier A, Konstantinides S, et al. ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008; 29(18): 2276–2315.
  6. Jiménez D, Lobo JL, Monreal M, et al. PROTECT investigators. Prognostic significance of multidetector CT in normotensive patients with pulmonary embolism: results of the protect study. Thorax. 2014; 69(2): 109–115.
  7. Özsu S, Kırış A, Bülbül Y, et al. Relationship between cardiac troponin-T and right ventricular Tei index in patients with hemodynamically stable pulmonary embolism: an observational study. Anadolu Kardiyol Derg. 2012; 12(8): 659–665.
  8. Vedovati MC, Germini F, Agnelli G, et al. Prognostic role of embolic burden assessed at computed tomography angiography in patients with acute pulmonary embolism: systematic review and meta-analysis. J Thromb Haemost. 2013; 11(12): 2092–2102.
  9. Klok FA, Djurabi RK, Nijkeuter M, et al. High D-dimer level is associated with increased 15-d and 3 months mortality through a more central localization of pulmonary emboli and serious comorbidity. Br J Haematol. 2008; 140(2): 218–222.
  10. Ozsu S, Karaman K, Mentese A, et al. Combined risk stratification with computerized tomography /echocardiography and biomarkers in patients with normotensive pulmonary embolism. Thromb Res. 2010; 126(6): 486–492.
  11. Konstantinides S, Geibel A, Heusel G, et al. Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002; 347(15): 1143–1150.
  12. Vedovati MC, Becattini C, Agnelli G, et al. Multidetector CT scan for acute pulmonary embolism: embolic burden and clinical outcome. Chest. 2012; 142(6): 1417–1424.
  13. Wanless RB, Anand IS, Poole-Wilson PA, et al. Haemodynamic and regional blood flow changes after acute pulmonary microembolism in conscious rabbits. Cardiovasc Res. 1988; 22(1): 31–36.
  14. Perkett EA, Brigham KL, Meyrick B, et al. Continuous air embolization into sheep causes sustained pulmonary hypertension and increased pulmonary vasoreactivity. Am J Pathol. 1988; 132(3): 444–454.
  15. Berghaus TM, Haeckel T, Behr W, et al. Central thromboembolism is a possible predictor of right heart dysfunction in normotensive patients with acute pulmonary embolism. Thromb Res. 2010; 126(3): e201–e205.
  16. Becattini C, Agnelli G. Acute pulmonary embolism: risk stratification in the emergency department. Intern Emerg Med. 2007; 2(2): 119–129.
  17. Masotti L, Righini M, Vuilleumier N, et al. Prognostic stratification of acute pulmonary embolism: focus on clinical aspects, imaging, and biomarkers. Vasc Health Risk Manag. 2009; 5(4): 567–575.
  18. Palmieri V, Gallotta G, Rendina D, et al. Troponin I and right ventricular dysfunction for risk assessment in patients with nonmassive pulmonary embolism in the Emergency Department in combination with clinically based risk score. Intern Emerg Med. 2008; 3(2): 131–138.
  19. Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014; 12(4): 459–468.
  20. Worster A, Smith C, Silver S, et al. Evidence-based emergency medicine/critically appraised topic. Thrombolytic therapy for submassive pulmonary embolism? Ann Emerg Med. 2007; 50(1): 78–84.
  21. Hamel E, Pacouret G, Vincentelli D, et al. hrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest. 2001; 120(1): 120–125.
  22. Cao Y, Zhao H, Gao W, et al. Systematic review and meta-analysis for thrombolysis treatment in patients with acute submassive pulmonary embolism. Patient Prefer Adherence. 2014; 8: 275–282.
  23. Ucar EY, Araz O, Akgun M, et al. Low-molecular-weight heparin use with thrombolysis: is it effective and safe? Ten years' clinical experience. Respiration. 2013; 86(4): 318–323.